Stock PFE PFIZER, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pfizer, Inc.

Equities

PFE

US7170811035

Market Closed - Nyse
Other stock markets
 04:00:39 2024-04-23 pm EDT 		5-day change 1st Jan Change
26.32 USD +0.23% Intraday chart for Pfizer, Inc. +3.54% -8.58%
Apr. 23 Edwards Lifesciences Corporation: The story continues Our Logo
Apr. 23 Pfizer vs Moderna battle over COVID vaccine patents begins in UK RE

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • This company will be of major interest to investors in search of a high dividend stock.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's enterprise value to sales, at 3.27 times its current sales, is high.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PFIZER, INC. Stock Pfizer, Inc.
-8.58% 149B
C+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.92% 659B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.68% 557B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.59% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.38% 322B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.39% 297B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+6.30% 215B
B+
NOVARTIS AG Stock Novartis AG
+4.80% 210B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-6.05% 200B
A+
AMGEN INC. Stock Amgen Inc.
-4.99% 146B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. Ratings Pfizer, Inc.